Novo Nordisk has announced that it will maintain its popular insulin brand, Mixtard, in vial format in the Indian market, even as it discontinues the Penfill cartridges. This move comes amidst worries regarding the withdrawal of commonly used insulin items. The company’s objective is to streamline its insulin offerings to address the rising need from patients and guarantee a steady drug supply, with a focus on modern treatments.